Concepedia

Ewa Karwatowska‐Prokopczuk

EK

39

Publications

4.3K

Citations

28

H-Index

1988

Active since

Affiliations

Ionis Pharmaceuticals (United States)(Current)

University of California San Diego

Brigham and Women's Hospital

Thrombolysis in Myocardial Infarction Study Group

Akebia Therapeutics (United States)

Ewa Karwatowska‐Prokopczuk is an author at Ionis Pharmaceuticals (United States) specializing in medicine, pharmacology, and cardiovascular disease.

ORCID

Top concepts

Publications per year

1988–2024

39

Publications

39

Lipoprotein(a) Reduction in Persons with Cardiovascular Disease

Sotirios Tsimikas, Ewa Karwatowska‐Prokopczuk, Ioanna Gouni‐Berthold et al. · New England Journal of Medicine · 2020 · 924 citations · Full text

Neuropeptide Y

Zofia Żukowska-Grójec, Ewa Karwatowska‐Prokopczuk, Wesley Rose et al. · Circulation Research · 1998 · 372 citations

, , +14

Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to <i>ANGPTL3</i> mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia

Daniel Gaudet, Ewa Karwatowska‐Prokopczuk, Seth J. Baum et al. · European Heart Journal · 2020 · 258 citations · Full text

Efficacy of Ranolazine in Patients With Chronic Angina

Sean R. Wilson, Benjamin M. Scirica, Eugene Braunwald et al. · Journal of the American College of Cardiology · 2009 · 196 citations

, , +3

Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk

Jean‐Claude Tardif, Ewa Karwatowska‐Prokopczuk, Eric St Amour et al. · European Heart Journal · 2021 · 190 citations · Full text

Rows per page

1–5 of 39